To assess the activity of SPAG5, we performed loss-of-function assays using siRNA-mediated targeting of SPAG5 in four different breast cancer cell lines: MDA-MB-231, MDA-MB-468, MCF-7, and SUM-159PT. This evidence concerns the gene SPAG5 and breast cancer.